On June 15, 2018 Amphivena Therapeutics reported that initial data from the dose-escalation portion of the First-in-Human Phase 1 trial (AMV564-101, NCT03144245) evaluating AMV564 in patients with relapsed and/or refractory acute myeloid leukemia (AML) in an oral presentation at the 23rd European Hematology Association (EHA) (Free EHA Whitepaper) meeting in Stockholm (Abstract S859) (Press release, Amphivena Therapeutics, JUN 15, 2018, View Source [SID1234527362]). The data from 17 patients treated within 5 cohorts demonstrate that AMV564 engages and activates T cells resulting in leukemic cytoreduction. AMV564 is a bivalent, bispecific (2X2) T-cell engager that binds both CD33 and CD3 with strong avidity and results in T-cell directed lysis of CD33-expressing myeloid cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AMV564 was designed to produce a longer half-life than the small monovalent bispecific T-cell engagers. Here, at EHA (Free EHA Whitepaper), the initial data presentation represents our first clinical proof-of-concept of T-cell engagement, T-cell activation, and leukemic cytoreduction in patients with heavily pre-treated, chemotherapy resistant AML," said Eric J. Feldman M.D., Chief Medical Officer at Amphivena.
Peter Westervelt, M.D. Ph.D., Professor of Medicine at Washington University in St. Louis, and a Principal Investigator for the study, presented on behalf of the study team. He said, "AMV564 is a potent T-cell engager that is well tolerated by patients with AML. The pharmacokinetics are unprecedented with a gradual rise to steady state drug levels that may help mitigate cytokine release syndrome. The 0%, 30-day mortality rate in this high-risk population of AML patients is extremely encouraging, and we are seeing evidence of anti-leukemic activity even at very low doses."
About AMV564-101
AMV564-101 is a First-in-Human dose escalation and dose expansion Phase 1 trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMV564 in patients with relapsed and/or refractory AML (NCT03144245). AMV564 is administered by continuous intravenous infusion (CIV) for 14 consecutive days for up to 2 induction cycles. Key inclusion/exclusion criteria are: adults with relapsed and/or refractory AML after 1-2 prior induction regimens (with a standard anthracycline-based regimen or hypomethylating agent) and no more than 2 prior salvage regimens. The Phase 1 study is currently open at Washington University, MD Anderson Cancer Center, and Weill-Cornell Medical College.